1. Home
  2. XAIR vs NEUP Comparison

XAIR vs NEUP Comparison

Compare XAIR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$1.35

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.55

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
NEUP
Founded
2011
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
10.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
NEUP
Price
$1.35
$4.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$11.00
$28.00
AVG Volume (30 Days)
1.2M
211.0K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,802,000.00
$15,649,448.00
Revenue This Year
$261.11
N/A
Revenue Next Year
$151.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
N/A
52 Week Low
$1.19
$2.90
52 Week High
$11.56
$21.40

Technical Indicators

Market Signals
Indicator
XAIR
NEUP
Relative Strength Index (RSI) 30.99 37.91
Support Level $1.19 $4.13
Resistance Level $1.38 $4.59
Average True Range (ATR) 0.11 0.38
MACD 0.01 0.30
Stochastic Oscillator 20.15 34.29

Price Performance

Historical Comparison
XAIR
NEUP

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: